Underwritten by the Drugmakers

China's Premium Drug Channel Is Being Underwritten by the Drugmakers

China's Commercial Health Insurance Innovative Drug List gives CAR-Ts and rare-disease drugs a state-endorsed premium price, but city insurers are dropping listed drugs, hospitals barely stock them and filings have halved; the emerging design makes the manufacturer the payer of last resort. Exposed: pharma pricing, cell therapy, insurers.

The consensus reading of China's Commercial Health Insurance Innovative Drug List is that Beijing has opened a premium lane: a state-curated formulary for CAR-Ts and rare-disease drugs priced beyond what basic insurance will carry, with the State Council endorsing launch prices that match high investment and high risk. The signal beneath it is that the lane has no payer. Eight months in, city Huiminbao schemes paid no more for innovative drugs than the year before, Shanghai's flagship scheme dropped a CAR-T, and filings for the second list fell by more than half. The remedy on the table asks the drugmaker to carry claims above a cap; the premium price is worth only what that risk-share allows.

Signal Identification

A regulatory pivot with a financial mechanism underneath. China is building a two-formulary system: basic insurance covers the basics, and a state-endorsed but non-binding list points commercial insurers at the rest. The weak signal is who ends up holding the claims. With insurers retreating and hospitals rationing quietly, the first year's design pushes tail risk onto the manufacturer and turns the headline premium price into a nominal one.

Time horizon: 1-3 years (second list negotiated from 5 September 2026 and due around year-end; Medical Security Law and 2027 Huiminbao renewals from January 2027; C-list-to-NRDL transfers 2027-2028)

Plausibility band: Medium–High

Geographic / Jurisdictional Scope: China as the primary jurisdiction (NHSA and NFRA policy, Shanghai and other city Huiminbao schemes, Chinese and multinational manufacturers selling there); spillover to multinational launch-price and reference-price planning, to Chinese biotech revenue forecasts and valuations, to reinsurers writing Chinese health risk, and to Hong Kong and Asian private payers

PrimaryChina (NHSA, NFRA)Shanghai / city Huiminbao schemesChinese and MNC pharma

SpilloverMNC launch-price planningChina biotech valuationsReinsurers writing China healthHong Kong / Asia private payers

Sectors exposed:

Pharma pricing and market accessCell and gene therapy makersChinese biotechHealth insurers and reinsurersHuiminbao operators and TPAsHospital pharmacy and formulary committeesBiopharma investors and analysts

What's Changing

The state has named the payer without binding it. On 4 September NHSA deputy head Li Tao said the basic list had added 949 drugs, 199 of them innovative, since 2018, and that for innovative drugs beyond its scope the agency would recommend that commercial health insurance pays first, with a Medical Security Law in force from 1 January 2027 (National Healthcare Security Administration, 04/09/2026). Price consultation for the second list opened on 5 September, expected to take four to five days (Sina Finance (Yicai), 03/09/2026).

The funnel narrowed. In the first round 121 therapies passed review, 42 (34.7%) filed for the commercial list only and 19 (13.5%) were listed; the catalogue does not bind insurers, and expected price cuts were 20% to 40% against 50% to 70% for NRDL entry (Avalere Health, 18/03/2026). For 2026, 57 drugs sought the commercial list and 53 passed (National Healthcare Security Administration, 29/06/2026); with dual filings counted, 61 applications against 141 a year earlier (Sina Finance (National Business Daily), 16/06/2026).

The money did not follow. Huiminbao schemes paid under 2 billion yuan (18亿元) for innovative drugs in 2025, flat on the year; listed drugs were stocked in 12.3% of tertiary hospitals and under 1% of primary facilities; and a city scheme that had paid more than 40 million yuan on 80-plus Yescarta claims removed the drug for 2026 (Sina Finance (China Business Journal), 04/07/2026). Shanghai's Huhuibao dropped Yescarta and Fabrazyme, and prescribers wary of hospital metrics left the list with no prescriptions (Sina Finance (National Business Daily), 16/06/2026).

Two rounds of the C-list: the funnel narrows, the payer steps back

Sources: NHSA notice of 29 June 2026; Avalere Health (18 March 2026); National Business Daily and China Business Journal reports via Sina Finance (16 June and 4 July 2026); Yicai via Sina Finance (3 September 2026).

Disruption Pathway

Stage one runs to year-end: the second list is assembled by price consultation from a pool manufacturers have already thinned, with only 17 products filed for the commercial list alone (Sina Finance (National Business Daily), 16/06/2026). Stage two, through 2027, is renewal season: the Medical Security Law takes effect, city schemes reprice or drop the drugs that overran their estimates, and the insurance association's catalogue, built on a claims cap above which the drugmaker pays, becomes the template (Sina Finance (China Business Journal), 04/07/2026). Stage three, 2027 to 2028, is the bridge: listed drugs can file for the basic list without the five-year wait, so the commercial list becomes an antechamber to an NRDL price cut.

Stress concentrates on cell-therapy makers whose China revenue leans on a few city schemes, on insurers pricing special-drug liability without claims history, and on hospitals whose cost-per-case and drug-share metrics still count listed drugs. Two adaptations follow: cap-and-excess contracts in which the seller reinsures its own product, and case-by-case exemptions from bundled payment for cases using new drugs, which the NHSA now promises to enforce (National Healthcare Security Administration, 04/09/2026).

Why This Matters Now

Pharma boards should treat a C-list slot as a contingent liability rather than a pricing win: model China revenue on listed products net of caps, rebates and the NRDL cut that follows the bridge, because a Chinese launch price booked as a list price is a number no payer has agreed to. Cell-therapy companies should map which city schemes carry their claims and what the 2027 renewals will do to them. Insurers and reinsurers, named first payer without a mandate, should decide what they will write, at what cap, before the association's catalogue decides for them. On the available evidence the premium tier is real in law and nominal in cash.

Decision-action posture for this signal: Prepare — the second list and the 2027 renewals land within twelve months; the trigger to Decide is publication of the second list with fewer additions than the first, or adoption of cap-and-excess terms in the insurance association's catalogue.

Counter-Argument

The strongest objection is that year one of any formulary consolidates before it expands (Avalere Health, 18/03/2026), and that the 2026 cycle now lets listed drugs move to the basic list, so fewer filings reflect sorting rather than failure (Sina Finance (National Business Daily), 16/06/2026). Health premiums grew 6.0% in 2025 and should grow 6.5% to 7.5% in 2026 (Swiss Re Institute, 20/07/2026), individual medical policies raised innovative-drug payments 40% (Sina Finance (China Business Journal), 04/07/2026), and the State Council wants C-list landing accelerated (Pharmaceutical Executive, 11/06/2026).

Premium growth is not claims growth for listed drugs, and Swiss Re expects protection products to stay subdued. The bridge to the basic list confirms the point: a channel whose best outcome is graduation to a 50% to 70% price cut is a waiting room, not a market. The fix the industry has settled on, caps with the manufacturer paying the excess, is the signal itself: the payer of last resort is the seller.

Implications

This is durable change in how China pays for premium medicines, not a launch-year wobble. A two-formulary system is now written into statute, and the premium tier is state-curated, non-binding on insurers (Avalere Health, 18/03/2026) and, on this scan's reading, funded at the margin by the manufacturers whose products sit on it. The inflection window runs from the second list at year-end through the 2027 renewals. Makers of time-limited, capped therapies with real-world evidence gain, as do insurers with claims capability; single-product cell-therapy companies reliant on city schemes, and multinationals expecting NRDL-free premium revenue, carry the loss.

Early Indicators to Monitor

A second list with fewer additions than the first, or listed firms disclosing claim-cap or outcomes terms.
2027 Huiminbao renewals in Shanghai, Shenzhen or Guangzhou removing or capping listed CAR-Ts.
The China Insurance Association's drug catalogue adopting cap-and-excess risk-sharing as its standard clause.
Official data showing tertiary-hospital stocking of listed drugs still below 20% at end-2026.
CAR-T makers' 2026 annual reports disclosing rebate or claim-cap liabilities to insurers.

Disconfirming Signals

Huiminbao innovative-drug payments for 2026 reported well above the flat 2025 level.
NFRA or NHSA making coverage of the list a condition of Huiminbao or standard medical policies.
Filings for the 2027 round recovering to the 2025 level.
Listed drugs stocked in a majority of tertiary hospitals by mid-2027.
Insurers launching products that cover the full list without manufacturer risk-share or claim caps.

Strategic Questions

Should you price for the list's nominal premium, or for the capped, risk-shared price an insurer will actually pay?
Which pipeline assets are worth a C-list slot as a bridge to the NRDL, and which should skip it?
Should insurers write listed drugs into 2027 products now, or wait until manufacturers fund the excess?

Keywords

China drug pricing; Commercial Health Insurance Innovative Drug List; C-list; NRDL; NHSA; Huiminbao; CAR-T; risk-sharing; launch pricing; Medical Security Law; market access

Bibliography

Source tiers: Tier 1, governments, regulators and intergovernmental bodies. Tier 2, think-tanks, academic institutes, major consultancies and quality data providers. Tier 3, quality journalism and specialist trade press. Tier 4, vendor, company and practitioner sources, used only as directional corroboration.

Tier 1 Transcript of the SCIO briefing on medical security in the 15th Five-Year Plan (Chinese). National Healthcare Security Administration (04/09/2026).
Tier 1 Notice of drugs passing formal review for the 2026 basic and commercial drug lists (Chinese). National Healthcare Security Administration (29/06/2026).
Tier 2 Early learnings from China's new Commercial Health Insurance Innovative Drug Catalogue. Avalere Health (18/03/2026).
Tier 2 China insurance in 2026: resilience amid structural divergence (sigma). Swiss Re Institute (20/07/2026).
Tier 3 Filings for the 2026 commercial-insurance drug list fall by more than half (National Business Daily, Chinese). Sina Finance (16/06/2026).
Tier 3 Tracking the commercial-insurance drug list: the last mile (China Business Journal, Chinese). Sina Finance (04/07/2026).
Tier 3 China Pharma Trends: Premium Pricing and Priority Access for True Innovations. Pharmaceutical Executive (11/06/2026).
Tier 3 2026 reimbursement negotiations to open on 5 September (Yicai, Chinese). Sina Finance (03/09/2026).